troglitazone has been researched along with cyclin d1 in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 12 (80.00) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Breyer, MD; Breyer, RM; Davis, L; Guan, YF; Zhang, YH | 1 |
| Collins, AR; Hsueh, WA; Kim, S; Law, RE; Liu, Z; Van Herle, AJ; Wakino, S; Yin, F | 1 |
| Hiraoka, S; Kitamura, S; Kiyohara, T; Matsuzawa, Y; Miyazaki, Y; Nagasawa, Y; Shinomura, Y; Takakura, R; Toyota, M | 1 |
| Kitamura, S; Kiyohara, T; Matsuzawa, Y; Miyazaki, Y; Nagasawa, Y; Shinomura, Y; Toyota, M | 1 |
| Bae, MA; Rhee, H; Song, BJ | 1 |
| Hirose, Y; Katayama, M; Kohno, H; Kuno, T; Mori, H; Qiao, Z; Sakata, K; Shibata, T; Sugie, S; Tanaka, T; Yamada, Y; Yoshida, K | 1 |
| Dono, K; Hayashi, N; Monden, M; Nagano, H; Nakamori, S; Okami, J; Sakon, M; Takahashi, Y; Tsujie, M; Umeshita, K | 1 |
| Pestell, RG; Pradeep, A; Rana, B; Sharma, C | 1 |
| Fisher, PB; Han, S; Roman, J; Sidell, N | 1 |
| Fischer, SM; He, G; Thuillier, P | 1 |
| Brueggemeier, RW; Chen, CS; Chen, KF; Huang, JW; Kulp, SK; Shapiro, CL; Shiau, CW; Yang, YT | 1 |
| Chen, CS; Chen, CY; Chiu, HC; Huang, JW; Shiau, CW; Wang, DS; Yang, J | 1 |
| Chang, KC; Eun, SY; Ham, SA; Kang, ES; Kim, GH; Kim, HJ; Kim, JH; Lee, HT; Lee, JH; Seo, HG; Woo, IS | 1 |
| Boisbrun, M; Chapleur, Y; Colin, C; Flament, S; Grillier-Vuissoz, I; Kuntz, S; Lecomte, J; Salamone, S | 1 |
| Aktas, BH; Grubissich, L; Halperin, JA; Harbinski, F; Ozdelen, E; Qiao, Y; Schubert, R; Sevinc, S; Singer, S | 1 |
15 other study(ies) available for troglitazone and cyclin d1
| Article | Year |
|---|---|
Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death.
Topics: Alitretinoin; Antineoplastic Agents; Apoptosis; Carcinoma, Transitional Cell; Carrier Proteins; Cell Death; Chromans; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA; DNA, Complementary; Dose-Response Relationship, Drug; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; G1 Phase; Humans; Immunoblotting; In Situ Hybridization; Ligands; Luciferases; Myelin P2 Protein; Neoplasm Proteins; Nicotinic Acids; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Ribonucleases; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transfection; Tretinoin; Troglitazone; Tumor Cells, Cultured; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 1999 |
Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cell Separation; Cell Survival; Chromans; Cyclin D1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Ethanol; Flow Cytometry; G1 Phase; Humans; Ligands; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-jun; Receptors, Cytoplasmic and Nuclear; Retinoblastoma Protein; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Transfection; Troglitazone; Tumor Cells, Cultured | 2001 |
PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells.
Topics: Animals; Blotting, Northern; Blotting, Western; Cell Division; Cell Line; Cell Line, Transformed; Cell Nucleus; Chromans; Cyclin D1; DNA, Complementary; Dose-Response Relationship, Drug; Epidermal Growth Factor; Epithelial Cells; Flow Cytometry; Humans; Hypoglycemic Agents; Intestines; Ligands; Luciferases; Plasmids; Promoter Regions, Genetic; ras Proteins; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transfection; Troglitazone | 2001 |
Peroxisome proliferator-activated receptor gamma reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1.
Topics: Alitretinoin; Animals; Antineoplastic Agents; Blotting, Northern; Blotting, Western; Carcinoma; Cell Division; Chromans; Cyclin D1; Dose-Response Relationship, Drug; Drug Synergism; G1 Phase; Humans; Pancreatic Neoplasms; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection; Tretinoin; Troglitazone; Tumor Cells, Cultured | 2002 |
Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Chromans; Cyclin A; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; G1 Phase; Humans; Liver Neoplasms; Protein Serine-Threonine Kinases; Rats; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2003 |
Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide.
Topics: 4-Nitroquinoline-1-oxide; Animals; Antineoplastic Agents; Bromodeoxyuridine; Carcinogens; Chromans; Cyclin D1; Cyclooxygenase 2; DNA-Binding Proteins; Incidence; Isoenzymes; Ligands; Male; Precancerous Conditions; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Inbred F344; Receptors, Cytoplasmic and Nuclear; Thiazolidinediones; Tongue; Tongue Neoplasms; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2003 |
Growth inhibition of pancreatic cancer cells through activation of peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway.
Topics: Alitretinoin; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Cell Division; Chromans; Cyclin D1; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Nuclear Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Tretinoin; Troglitazone; Tumor Cells, Cultured | 2003 |
Peroxisome proliferator-activated receptor gamma activation modulates cyclin D1 transcription via beta-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes.
Topics: Animals; beta Catenin; Blotting, Western; Cell Division; Cell Line; Chromans; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclin D1; Cytoskeletal Proteins; Enzyme Activation; Enzyme Inhibitors; Genes, Reporter; Hepatocytes; Humans; Hypoglycemic Agents; Ligands; Liver; Luciferases; Mice; Mutation; Okadaic Acid; Plasmids; Receptors, Cytoplasmic and Nuclear; Serine; Thiazolidinediones; Trans-Activators; Transcription Factors; Transcription, Genetic; Transfection; Troglitazone | 2004 |
Ligands of peroxisome proliferator-activated receptor gamma inhibit lung cancer cell growth and induce apoptosis by stimulation of P21 expression.
Topics: Antineoplastic Agents; Apoptosis; Chromans; Cyclin D1; Humans; Lung Neoplasms; Prostaglandin D2; Proto-Oncogene Proteins p21(ras); Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazolidinediones; Transcription Factors; Troglitazone | 2004 |
Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes.
Topics: Animals; Antineoplastic Agents; Cell Division; Cells, Cultured; Chromans; Cyclin D1; Gene Expression; Keratinocytes; Mice; PPAR gamma; Thiazolidinediones; Transfection; Troglitazone | 2004 |
Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Chromans; Cyclin D1; Down-Regulation; Female; Humans; PPAR gamma; Proteasome Endopeptidase Complex; Thiazolidinediones; Troglitazone | 2005 |
Development of small-molecule cyclin D1-ablative agents.
Topics: Antineoplastic Agents; Benzopyrans; Cell Line, Tumor; Cell Proliferation; Chromans; Cyclin D1; Humans; Hydrolysis; Molecular Conformation; PPAR gamma; Proteasome Endopeptidase Complex; Stereoisomerism; Structure-Activity Relationship; Thiazolidinediones; Troglitazone | 2006 |
Phorbol ester potentiates the growth inhibitory effects of troglitazone via up-regulation of PPARgamma in A549 cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromans; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Phorbol Esters; Phosphatidylinositol 3-Kinases; PPAR gamma; Reactive Oxygen Species; Thiazolidinediones; Troglitazone; Up-Regulation | 2006 |
New troglitazone derivatives devoid of PPARĪ³ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
Topics: Antineoplastic Agents; Biotinylation; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Cyclin D1; Dose-Response Relationship, Drug; Estrogen Receptor alpha; Estrogens; Female; Humans; Inhibitory Concentration 50; Neoplasms, Hormone-Dependent; PPAR gamma; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Thiazolidinediones; Transfection; Troglitazone | 2010 |
Small-Molecule targeting of translation initiation for cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chromans; Clotrimazole; Cyclin D1; Disease Models, Animal; Eicosapentaenoic Acid; Eukaryotic Initiation Factor-2; Female; Humans; Mice; Mice, Inbred DBA; Peptide Chain Initiation, Translational; Phosphorylation; Protein Biosynthesis; Random Allocation; Thiazolidinediones; Troglitazone; Xenograft Model Antitumor Assays | 2013 |